Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury
JAMA · 09.12.2025 · 334 (22) · 2000
DOI: 10.1001/jama.2025.20231 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 09.12.2025. Verfasst von Boris Jung und 39 weiteren Autor:innen. Beteiligte Einrichtung: Medical ICU, Lapeyronie University Hospital, PhyMedExp, Montpellier University, Montpellier, France. Hauptthemen laut MEDLINE: Acidosis, Acute Kidney Injury, Sodium Bicarbonate. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The effect of sodium bicarbonate infusion on outcome in patients with severe metabolic acidemia and moderate to severe acute kidney injury is unknown.
Objective
To determine whether sodium bicarbonate infusion is associated with day 90 all-cause mortality in patients with severe metabolic acidemia and moderate to severe acute kidney injury. Design, Setting, and Participants Randomized, open-label, clinical trial conducted with 640 patients in 43 French intensive care units from October 6, 2019, to December 19, 2023, with 90-day follow-up. The last date of follow-up was June 17, 2024. Adults with severe metabolic acidemia (defined as pH ≤7.20) and moderate to severe acute kidney injury were enrolled.
Intervention
Patients were randomized 1:1 to receive either intravenous sodium bicarbonate infusion or no sodium bicarbonate to target an arterial pH of 7.30 or higher. Main Outcomes and Measures The primary outcome was day 90 all-cause mortality. Secondary outcomes included day 28 and day 180 all-cause mortality; use of organ support therapy, vasopressors, or invasive mechanical ventilation; intensive care unit and hospital length of stay; intensive care unit–acquired infections; fluid balance; day-7 Sequential [Sepsis-related] Organ Failure Assessment score (6 organ systems’ function is evaluated and scored from 0 [no dysfunction] to 4 [failure]; total score ranges from 0 [normal] to 24 [maximum failure]); and major adverse kidney events on day 90.
Results
Among 640 randomly assigned patients, 627 were analyzed (313 in the control group and 314 in the bicarbonate group). The median age was 67 years (IQR, 59-74 years); 194 of 314 patients (62%) in the bicarbonate group and 185 of 313 controls (59%) were male. In the primary analysis, day 90 all-cause mortality was 195 of 314 patients (62.1%) in the bicarbonate group and 193 of 313 (61.7%) in the control group (absolute difference, 0.4; 95% CI, −7.2 to 8.0; P = .91). There was no evidence of a group effect on day 28 or day 180 all-cause mortality. Among 18 secondary outcomes, kidney replacement therapy was used in 109 of 314 (35%) bicarbonate group patients and 157 of 313 (50%) controls (absolute difference, −15.5; 95% CI, −23.1 to −7.8). No evidence of a group effect was found on other secondary outcomes, including adverse events. Conclusions and Relevance For patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not affect mortality. Trial Registration ClinicalTrials.gov Identifier: NCT04010630
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical ICU, Lapeyronie University Hospital, PhyMedExp, Montpellier University, Montpellier, France.
- Centre Hospitalier Universitaire (CHU), Departement Anesthesie et Réanimation, Estaing Hospital, Clermont-Ferrand, France.
- Université Clermont Auvergne, CNRS, INSERM U-1103, Clermont-Ferrand, France.
- Intensive Care Unit, Department of Anesthesiology and Critical Care Medicine B (DAR B), Saint-Eloi Hospital, Montpellier, France.
- University Teaching Hospital of Montpellier, PhyMedExp, Montpellier, INSERM U1046, Montpellier, France.
- Medical Intensive Care Unit, La Croix Rousse Hospital, Lyon, France.
Zitieren
APA
Jung, B., Jabaudon, M., De Jong, A., Bitker, L., Audard, J., Klouche, K., Sarton, B., Guitton, C., Lasocki, S., Rieu, B., Canet, E., Jeantrelle, C., Roquilly, A., Mayaux, J., Verdonk, F., Pottecher, J., Ferrandiere, M., Riu, B., Garcon, P., …, & BICARICU-2 Study Group (2025). Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury. JAMA, 334(22), 2000. https://doi.org/10.1001/jama.2025.20231
Vancouver
Jung B, Jabaudon M, De Jong A, Bitker L, Audard J, Klouche K, et al. Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury. JAMA. 2025;334(22):2000. doi:10.1001/jama.2025.20231
BibTeX
@article{Jung2025,
author = {Jung, Boris and Jabaudon, Mathieu and De Jong, Audrey and Bitker, Laurent and Audard, Jules and Klouche, Kada and Sarton, Benjamine and Guitton, Christophe and Lasocki, Sigismond and Rieu, Benjamin and Canet, Emmanuel and Jeantrelle, Caroline and Roquilly, Antoine and Mayaux, Julien and Verdonk, Franck and Pottecher, Julien and Ferrandiere, Martine and Riu, Beatrice and Garcon, Pierre and Assefi, Mona and Detouche, Philippe and Forel, Jean Marie and Roger, Claire and Bourenne, Jeremy and Jacquier, Sophie and Bougon, David and Rolle, Amelie and Corne, Philippe and Benchabane, Nacim and Richard, Jean Christophe and Asehnoune, Karim and Chanques, Gerald and Reignier, Jean and Belafia, Foud and Fosset, Maxime and Huguet, Helena and Futier, Emmanuel and Molinari, Nicolas and Jaber, Samir and BICARICU-2 Study Group, BICARICU-2 Study Group},
title = {Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury},
journal = {JAMA},
year = {2025},
volume = {334},
number = {22},
pages = {2000},
doi = {10.1001/jama.2025.20231}
}
EUVIMED